| |
The Patent Handoff Now Drives the Income Case |
Dividend investors have a clear reason to watch AbbVie now. The company still generates large cash flow, but the old Humira cushion keeps shrinking after its 2023 U.S. loss of exclusivity. In 2025, AbbVie produced $19.0 billion in operating cash flow and paid $11.7 billion in dividends, so the payout remained covered, but the gap is not as effortless as it looked during Humira’s peak years. |
That matters because income stability in pharma often depends on product durability, not just current yield. AbbVie has already moved past the first shock of the patent cliff. The next test is whether replacement revenue is durable enough to keep supporting a rising payout. |
In this article, we explore AbbVie’s post-Humira transition, the role of Skyrizi and Rinvoq, the remaining concentration risk, and how those factors shape dividend stability. |
|
|
|
| |
|
|
|
| |
Don't Let Inflation Rewrite Your Retirement |
|
|
Inflation isn't a theory, it's a math problem. |
When prices rise, your purchasing power falls. And every extra dollar printed makes the ones you already own worth less. |
That's why many investors are protecting a portion of their retirement with physical gold inside their IRA. |
It's a simple hedge that has outlasted every market meltdown and currency reset in modern history. |
Reagan Gold Group makes the process easy, handling the entire rollover, paperwork, and insured storage setup for you. |
If you've worked hard to build your wealth, don't let silent inflation eat it away. |
Get the Free Inflation Survival Guide: Learn How to Add Gold to Your IRA |
|
|
|
| |
|
|
|
| |
Humira Is Still Shrinking the Old Cash Engine |
AbbVie said Humira revenue fell 49% in 2025, driven by continued biosimilar competition after the loss of exclusivity. Reuters also reported that Humira sales fell 25.9% year over year in the fourth quarter of 2025, showing that the erosion phase is still active even after the first big break lower. |
The interpretation is straightforward. Humira is no longer the growth issue. It is the runoff issue. That changes the income story because AbbVie is no longer protecting a legacy blockbuster. It is replacing that cash stream with newer assets that must now do more of the work. |
|
|
|
| |
|
| |
Skyrizi and Rinvoq Are Rebuilding the Base |
AbbVie's full-year 2025 earnings release showed Skyrizi revenue climbed approximately 50% to $17.6 billion, while Rinvoq revenue grew around 39% to $8.3 billion. The company had previously set a combined sales target of more than $31 billion for the two drugs by 2027, a goal the pair surpassed a year ahead of schedule. |
That is the core support for the income case. The replacement engine is real, and it is already large. But replacement is not the same as diversification. AbbVie is swapping one giant dependency for two very important ones. |
This table shows that AbbVie’s payout story has shifted from one aging pillar to two fast-growing ones. |
Product Driver |
2025 Trend |
Income Read-Through |
Humira |
Revenue down 49% |
Legacy cushion keeps fading |
Skyrizi |
Revenue up 50% |
Main source of replacement growth |
Rinvoq |
Revenue up 39% |
Adds scale and longer cash runway |
|
|
|
|
| |
|
| |
Concentration Risk Has Changed, Not Disappeared |
AbbVie’s business returned to growth in 2025, and the company described that rebound as part of its strategy after Humira’s patent loss. Reuters reported in September 2025 that Rinvoq gained U.S. exclusivity protection until 2037, extending one of the company’s most important cash-flow runways. |
That helps, but it does not remove concentration risk. A long patent runway supports visibility, yet it also makes the company more dependent on execution in immunology. If Skyrizi and Rinvoq keep growing, the dividend looks well supported. If either one faces slower uptake, pricing pressure, or a competitive setback, the room between operating cash flow and shareholder payouts can narrow faster than earnings headlines suggest. |
|
|
|
| |
|
| |
Pipeline Spending Still Competes with Payout Flexibility |
AbbVie declared $6.65 per share in dividends in 2025, up from $6.29 in 2024 and $5.99 in 2023. That record matters because it shows continued commitment to the payout even during the patent handoff. |
Still, capital flexibility is not unlimited. AbbVie spent heavily on acquired research and milestones, and its 2025 cash-flow statement shows $5.0 billion in acquired IPR&D and milestone expense. That means part of the cash story is still being used to defend the next growth cycle, not just to fund shareholder returns. |
A simple sequence explains the pressure: |
Humira declines reduce the old high-margin base Skyrizi and Rinvoq rebuild revenue and cash flow Pipeline and deal spending limit how much cushion is left over
|
|
|
|
| |
|
| |
Risks and Limitations |
Several factors could still weaken the income picture: |
Faster competition in immunology could slow replacement growth Pipeline spending can absorb cash even when revenue trends look solid Product concentration remains high despite Humira’s decline
|
|
|
|
| |
|
| |
Portfolio Translation |
For dividend portfolios, AbbVie still looks like a cash-generating large-cap pharmaceutical name with meaningful payout support. The support appears firmer where Skyrizi and Rinvoq continue to scale, and less firm where concentration, competition, or pipeline spending tighten coverage. The stock’s income profile now depends less on a broad legacy cushion and more on a successful transfer from one drug era to the next. |
|
|
|
| |
|
| |
Conclusion |
AbbVie has already crossed the first stage of the patent cliff. The harder stage is making sure its new leaders do not become a new source of dependence. Income stability still has real support here, but that support now rests on fewer moving parts than the old AbbVie story did. |
|
|
|
| |
|
|
|
Reagan Gold Group does not provide financial, legal, or tax advice. This information is for educational purposes only and should not be considered investment advice. All investments carry risk, including loss of principal. Past performance is not indicative of future results. Consult your licensed financial advisor before making investment decisions. |
This is an advertisement.
If you no longer wish to receive promotional messages from this advertiser, please click here: Unsubscribe. Or write to: 2029 Century Park E Suite 400, Los Angeles, CA 90067 |
This action will filter out any further emails about this specific offer. You will still receive our regular communications. To stop all emails entirely, please use the unsubscribe link in the footer. |
|
